Display options
Cite
Abdallah A, Belal M, El Bastawisy A, et al. Plasma vascular endothelial growth factor 165 in advanced non-small cell lung cancer. Oncol Lett. 2014;7(6):2121-2129doi: 10.3892/ol.2014.2016.
Abdallah, A., Belal, M., El Bastawisy, A., & Gaafar, R. (2014). Plasma vascular endothelial growth factor 165 in advanced non-small cell lung cancer. Oncology letters, 7(6), 2121-2129. https://doi.org/10.3892/ol.2014.2016
Abdallah, Ahmed, et al. "Plasma vascular endothelial growth factor 165 in advanced non-small cell lung cancer." Oncology letters vol. 7,6 (2014): 2121-2129. doi: https://doi.org/10.3892/ol.2014.2016
Abdallah A, Belal M, El Bastawisy A, Gaafar R. Plasma vascular endothelial growth factor 165 in advanced non-small cell lung cancer. Oncol Lett. 2014 Jun;7(6):2121-2129. doi: 10.3892/ol.2014.2016. Epub 2014 Mar 31. PMID: 24932301; PMCID: PMC4049695.
Copy Download .nbib Format: NLM
Share it on

Oncol Lett. 2014 Jun;7(6):2121-2129. doi: 10.3892/ol.2014.2016. Epub 2014 Mar 31.

Plasma vascular endothelial growth factor 165 in advanced non-small cell lung cancer.

Oncology letters

Ahmed Abdallah, Mohamed Belal, Ahmed El Bastawisy, Rabab Gaafar

Affiliations

  1. Faculty of Pharmacy, Al-Azhar University, Cairo 11884, Egypt.
  2. Department of Medical Oncology, National Cancer Institute, Cairo University, Cairo 11796, Egypt.

PMID: 24932301 PMCID: PMC4049695 DOI: 10.3892/ol.2014.2016

Abstract

Currently, there is no serum marker that is routinely recommended for lung cancer. Therefore, the aim of the present study was to demonstrate that plasma vascular endothelial growth factor 165 (VEGF 165) may be a potential marker for advanced lung cancer. Lung cancer is the leading cause of cancer-related mortality worldwide, therefore, it is important to develop novel diagnostic techniques. The present prospective case control study included two groups of patients; a control group of healthy volunteers and a second group of patients with advanced non-small cell lung cancer (NSCLC). The plasma VEGF 165 levels were measured at baseline by ELISA prior to the first-line gemcitabine-cisplatin regimen. The high VEGF 165 expression level cut-off was >703 pg/ml, and the primary endpoint was used to compare the plasma VEGF 165 levels between the NSCLC patients and the control group subjects. The secondary endpoint was used to identify the correlations between high VEGF 165 levels and; clinical response (CR), progression-free survival (PFS) and overall survival (OS) in the advanced NSCLC patients. In total, patients with advanced NSCLC (n=35) were compared with a control group of age- and gender-matched healthy subjects (n=34). The follow-up period was between Oct 2009 and Oct 2012, with a median follow-up time of 10.5 months. The median plasma VEGF 165 level was 707 pg/ml in the NSCLC patients versus 48 pg/ml in the healthy control subjects (P<0.001). However, no significant correlation was found between the plasma VEGF 165 levels and CR (P<0.5), median PFS (P=1.00) or OS (P=0.70). Therefore, it was concluded that plasma VEGF 165 may serve as a potential diagnostic marker for advanced NSCLC.

Keywords: non-small cell lung cancer; vascular endothelial growth factor

References

  1. FASEB J. 1999 Jan;13(1):9-22 - PubMed
  2. Neuropathol Appl Neurobiol. 2002 Dec;28(6):452-60 - PubMed
  3. Anticancer Res. 1998 Mar-Apr;18(2A):1123-7 - PubMed
  4. Respirology. 2002 Jun;7(2):93-8 - PubMed
  5. J Clin Invest. 2007 Oct;117(10):2740-50 - PubMed
  6. J Cell Sci. 2001 Mar;114(Pt 5):853-65 - PubMed
  7. Eur J Cancer. 1998 Dec;34(13):2041-5 - PubMed
  8. Mol Biol Cell. 1993 Dec;4(12):1317-26 - PubMed
  9. CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 - PubMed
  10. Nat Med. 2003 Jun;9(6):669-76 - PubMed
  11. Lung Cancer. 2001 Dec;34 Suppl 2:S59-64 - PubMed
  12. Clin Chem. 2007 Aug;53(8):1433-9 - PubMed
  13. Lung Cancer. 2001 Dec;34 Suppl 4:S3-7 - PubMed
  14. Hum Pathol. 1995 Jan;26(1):86-91 - PubMed
  15. Curr Cancer Drug Targets. 2006 Jun;6(4):271-94 - PubMed
  16. Biochim Biophys Acta. 1998 Dec 22;1443(3):400-6 - PubMed
  17. Histol Histopathol. 2004 Jan;19(1):37-42 - PubMed
  18. Br J Cancer. 1998 Mar;77(6):956-64 - PubMed
  19. Neoplasma. 1997;44(5):295-8 - PubMed
  20. Nature. 1993 Apr 29;362(6423):841-4 - PubMed
  21. Cytokine Growth Factor Rev. 2005 Feb;16(1):77-89 - PubMed
  22. Acta Med Okayama. 2000 Jun;54(3):119-26 - PubMed
  23. Int J Cancer. 2000 Jul 20;89(4):389-94 - PubMed
  24. Lung Cancer. 2004 Jan;43(1):55-62 - PubMed
  25. Lung Cancer. 2006 Jul;53(1):91-6 - PubMed
  26. Neurol Res. 2005 Jun;27(4):371-7 - PubMed
  27. Clin Cancer Res. 1998 Dec;4(12):3017-24 - PubMed
  28. Chest. 2000 Oct;118(4):948-51 - PubMed
  29. Clin Cancer Res. 1998 Jun;4(6):1483-7 - PubMed
  30. Lung Cancer. 2002 Jul;37(1):57-63 - PubMed
  31. J Clin Invest. 1993 Jan;91(1):153-9 - PubMed
  32. Br J Cancer. 1998 Mar;77(6):998-1002 - PubMed
  33. J Pathol. 1999 Aug;188(4):369-77 - PubMed
  34. Clin Cancer Res. 1997 Jun;3(6):861-5 - PubMed
  35. Cancer Invest. 2006 Oct;24(6):576-80 - PubMed
  36. Neuropathol Appl Neurobiol. 2004 Apr;30(2):118-25 - PubMed
  37. Int J Oncol. 1998 Mar;12(3):541-4 - PubMed
  38. Ann Surg Oncol. 2001 Jan-Feb;8(1):72-9 - PubMed
  39. J Clin Oncol. 2001 Jan 15;19(2):432-41 - PubMed
  40. Br J Cancer. 1996 Apr;73(7):931-4 - PubMed
  41. Endocr Rev. 1997 Feb;18(1):4-25 - PubMed
  42. Lab Invest. 2000 Nov;80(11):1671-80 - PubMed
  43. Cancer Res. 2000 Jun 1;60(11):3088-95 - PubMed
  44. Ann Oncol. 2002 Oct;13(10):1550-7 - PubMed
  45. Folia Histochem Cytobiol. 2001;39 Suppl 2:100-1 - PubMed
  46. Br J Cancer. 1999 Jan;79(2):363-9 - PubMed
  47. Endocr Rev. 1992 Feb;13(1):18-32 - PubMed
  48. Clin Sci (Lond). 1998 Apr;94(4):395-404 - PubMed
  49. Lung Cancer. 2005 Oct;50(1):51-8 - PubMed
  50. J Thorac Cardiovasc Surg. 1998 May;115(5):1007-14 - PubMed
  51. Anticancer Res. 1998 Mar-Apr;18(2B):1251-4 - PubMed
  52. Respir Med. 2004 Jul;98(7):632-6 - PubMed
  53. Vet Pathol. 2008 Mar;45(2):131-9 - PubMed
  54. Lung. 2005 Jan-Feb;183(1):29-42 - PubMed
  55. Clin Cancer Res. 1996 Aug;2(8):1411-6 - PubMed
  56. Lung Cancer. 2009 Dec;66(3):314-8 - PubMed
  57. Clin Chem. 2003 Mar;49(3):523-5 - PubMed

Publication Types